#Immunotherapy #Private Placement #BioVaxys

BioVaxys Technology Corp. Adjusts Private Placement Offering

Vancouver, BC – December 11, 2024 – BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB) has announced a significant revision in its private placement offering initially revealed on November 18, 2024. This adjustment involves a decrease in the price per unit and an increase in the number of units available to prospective investors.

The company disclosed that the price for each unit has been reduced from CAD 0.07 to CAD 0.05. As a result of this adjustment, the number of units available for subscription will increase from 14,285,715 to 20 million units. This move reflects BioVaxys' unwavering intention to raise a total of CAD 1 million through this offering.

Each unit comprises one common share and an accompanying whole share purchase warrant. Investors holding these warrants will have the opportunity to convert them into additional shares at a price of CAD 0.15, valid for a two-year period following issuance.

BioVaxys continues to focus on applying the proceeds from this offering towards working capital requirements, which may also include finder’s fees related to this transaction. It is noteworthy that all securities issued as part of this offering will be subject to a hold period, which will expire four months and one day post-issuance, in compliance with applicable securities regulations.

The successful closing of the offering is contingent upon securing necessary regulatory approvals, including those from the Canadian Securities Exchange. The company has stipulated that this announcement does not constitute an offer to sell or solicit an offer to purchase any securities in the United States. Furthermore, the recently issued securities have not been registered under the U.S. Securities Act of 1933 and are not available for offer or sale in the U.S. unless they are registered or qualify for an exemption from registration requirements.

About BioVaxys Technology Corp.

BioVaxys Technology Corp., based in British Columbia, Canada, operates as a clinical-stage biopharmaceutical entity. The company is committed to enhancing patient outcomes through innovative immunotherapies that utilize its proprietary DPX™ immune-educating technology. This approach is directed toward treating cancer, infectious diseases, and other immune-related disorders. BioVaxys' DPX™ platform allows for the effective delivery of antigens, aiming to provoke strong immune responses that can lead to significant clinical advantages.

The common shares of BioVaxys are publicly traded on the Canadian Securities Exchange under the symbol